

Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction

Jasper Boeddinghaus^{1,2,3†}, Thomas Nestelberger^{1,3†}, Raphael Twerenbold^{1,3,4}, Johannes Tobias Neumann⁴, Bertil Lindahl⁵, Evangelos Giannitsis⁶, Nils Arne Sørensen⁴, Patrick Badertscher^{1,3}, Janina E. Jann^{1,3}, Desiree Wussler^{1,3}, Christian Puelacher^{1,3}, Maria Rubini Giménez^{1,3}, Karin Wildi^{1,3}, Ivo Strebel^{1,3}, Jeanne Du Fay de Lavallaz^{1,3}, Farah Selman¹, Zaid Sabti^{1,3}, Nikola Kozuharov^{1,3}, Eliska Potlukova^{1,2}, Katharina Rentsch⁷, Òscar Miró^{3,8}, F. Javier Martin-Sanchez^{3,9}, Beata Morawiec^{3,10}, Jiri Parenica^{3,11,12}, Jens Lohrmann¹, Wanda Kloos¹, Andreas Buser^{13,14}, Nicolas Geigy¹⁵, Dagmar I. Keller¹⁶, Stefan Osswald¹, Tobias Reichlin^{1,3}, Dirk Westermann⁴, Stefan Blankenberg⁴, and Christian Mueller^{1,3*}; for the APACE, BACC, and TRAPID-AMI Investigators[‡]

¹Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Petersgraben 4, 4031 Basel, Switzerland; ²Division of Internal Medicine, University Hospital Basel, University of Basel, Petersgraben 4, 4031 Basel, Switzerland; ³GREAT Network, Via Antonio Serra 54, 00191 Rome, Italy; ⁴Department of General and Interventional Cardiology, Hamburg University Heart Center, Martinistraße 52, 20246 Hamburg, Germany; ⁵Department of Medical Sciences, Uppsala University and Uppsala Clinical Research Centre, Uppsala University, Akademiska sjukhuset, Ing. 40, 5 tr, 751 85 Uppsala, Sweden; ⁶Medizinische Klinik III, University Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany; ⁷Laboratory Medicine, University Hospital Basel, University of Basel, Petersgraben 4, 4031 Basel, Switzerland; ⁸Emergency Department, Hospital Clinic, Calle Villarreal 170 08036 Barcelona, Catalonia, Spain; ⁹Servicio de Urgencias, Hospital Clínico San Carlos, Profesor Martín Lagos, S/N, 28040 Madrid, Spain; ¹⁰2nd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Katowice, ul. M. Curie-Skłodowskiej 9, 41-800 Zabrze, Poland; ¹¹Department of Cardiology, University Hospital Brno, Jihlavská 20, CZ - 625 00 Brno, Czech Republic; ¹²Medical Faculty, Masaryk University, Kamenice 5, 625 00 Brno-Bohunice, Czech Republic; ¹³Blood Transfusion Centre, Swiss Red Cross, Hebelstrasse 10, 4056 Basel, Switzerland; ¹⁴Department of Hematology, University Hospital Basel, University of Basel, Petersgraben 4, 4031 Basel, Switzerland; ¹⁵Emergency Department, Kantonsspital Liestal, Rheinstrasse 26, 4410 Liestal, Switzerland; and ¹⁶Emergency Department, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland

Received 4 October 2017; revised 28 December 2017; editorial decision 2 August 2018; accepted 5 August 2018; online publish-ahead-of-print 29 August 2018

See page 3795 for the editorial comment on this article (doi: 10.1093/eurheartj/ehy526)

Aims

We aimed to evaluate the impact of age on the performance of the European Society of Cardiology (ESC) 0/1h-algorithms and to derive and externally validate alternative cut-offs specific to older patients.

Methods and results

We prospectively enrolled patients presenting to the emergency department (ED) with symptoms suggestive of acute myocardial infarction in three large diagnostic studies. Final diagnoses were adjudicated by two independent cardiologists. High-sensitivity cardiac troponin (hs-cTn) T and I concentrations were measured at presentation and after 1 h. Patients were stratified according to age [<55 years (young), ≥ 55 to <70 years (middle-age), ≥ 70 years (old)]. Rule-out safety of the ESC hs-cTnT 0/1h-algorithm was very high in all age-strata: sensitivity 100% [95% confidence interval (95% CI) 94.9–100] in young, 99.3% (95% CI 96.0–99.9) in middle-age, and 99.3% (95% CI 97.5–99.8) in old patients. Accuracy of rule-in decreased with age: specificity 97.0% (95% CI 95.8–97.9) in young, 96.1% (95% CI 94.5–97.2) in middle-age, and 92.7% (95% CI 90.7–94.3) in older patients. Triage efficacy decreased with increasing age (young 93%, middle-age 80%, old 55%, $P < 0.001$). Similar results were found for the ESC hs-cTnT 0/1h-algorithm. Alternative, slightly higher cut-off concentrations optimized for older patients maintained very high safety of rule-out, increased specificity of rule-in ($P < 0.01$), reduced overall efficacy for hs-cTnT ($P < 0.01$), while maintaining efficacy for hs-cTnI. Findings were confirmed in two validation cohorts ($n = 2767$).

* Corresponding author. Tel: +41 61 328 65 49, Fax: +41 61 265 53 53, Email: christian.mueller@usb.ch

† The first two authors contributed equally to the study.

‡ The authors of the APACE, BACC, and TRAPID-AMI Investigators group are listed in the Acknowledgements section.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

Conclusion

While safety of the ESC 0/1h-algorithms remained very high, increasing age significantly reduced overall efficacy and the accuracy of rule-in. Alternative slightly higher cut-off concentrations may be considered for older patients, particularly if using hs-cTnI.

Clinical Trial Registration

<https://clinicaltrials.gov/ct2/show/NCT00470587>, number NCT00470587 and NCT02355457 (BACC).

Keywords

Age • High-sensitivity cardiac troponin • Guidelines • 0/1h-Algorithm • Diagnosis of AMI

Introduction

In patients presenting with symptoms suggestive of acute myocardial infarction (AMI), rapid identification of AMI as a life-threatening disorder, but also rapid and accurate rule-out of AMI has enormous medical and economic value.^{1–3} Recently, diagnostic strategies applying high-sensitivity cardiac troponin (hs-cTn) T or I assays, including the European Society of Cardiology (ESC) 0/1h-algorithms, have been developed and facilitate the early triage towards rule-out or rule-in of AMI.^{1–11}

Beyond the presence or absence of AMI, age seems to be the most important confounder of hs-cTnT and hs-cTnI blood concentrations.^{12–21} Mildly elevated hs-cTnT and hs-cTnI blood concentrations are common in elderly individuals without apparent ischaemic symptoms.^{2,3,12–21} Unfortunately, the impact of age on the diagnostic performance of the ESC 0/1h-algorithms is incompletely understood.

To address this major gap in knowledge, we prospectively investigated the impact of age on the performance of the ESC 0/1h-algorithms in a large multicentre diagnostic study using central adjudication. In a second step, the age-specific findings and aged-optimized alternative cut-off concentrations for older patients derived in this multicentre study were externally validated in two additional diagnostic studies.

Methods

Study design and oversight

We enrolled adult patients presenting with suspected AMI to the emergency department (ED) in three large prospective diagnostic studies carried out according to the principles of the Declaration of Helsinki and approved by the local ethics committees: Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE, main cohort),^{5,7–10,17,22–26} Biomarkers in Acute Cardiac Care (BACC, first validation cohort),²⁷ and High-sensitivity cardiac Troponin T assay for RAPID rule-out of AMI (TRAPID-AMI, second validation cohort).²⁸ Written informed consent was obtained from all patients.

The authors designed the study, gathered, and analysed the data according to the STARD guidelines²⁹ for studies of diagnostic accuracy (Supplementary material online, Table S1), vouched for the data and analysis, wrote the paper, and decided to publish. Routine clinical assessment and detailed methodological descriptions of all three cohorts are given in the Supplementary material online.

The ESC high-sensitivity cardiac troponin T and high-sensitivity cardiac troponin I 0/1h-algorithms

The concept of the ESC 0/1h-algorithms is described in detail in the Supplementary material online and shown in Supplementary material online, Figure S1.

Stratification of patients according to age

We aimed to stratify patients by age into three equally large cohorts. Based on previous findings from APACE^{5,8–10,22,25,30–33} we assumed that the following three age-strata should yield near-equal group-size: <55 years (young), ≥55 to <70 years (middle-age), and ≥70 years (old).

Statistical analysis

Safety for rule-out was quantified by the resulting sensitivity [and negative predictive value (NPV)], accuracy for rule-in was quantified by the resulting specificity [and positive predictive value (PPV)] for non-ST-segment elevation myocardial infarction (NSTEMI) and overall efficacy was quantified by the percentage of patients triaged either towards rule-out or rule-in by the respective strategy. Time since chest pain onset (cpo) was determined at the time of first study blood draw. In the main cohort, subgroup analyses were performed in early presenters (cpo ≤2 h), late presenters (cpo >6 h), and in very old patients (age ≥80 years).

All hypothesis testing was two-tailed, and *P*-values of less than 0.05 were considered to indicate statistical significance without adjustments for multiple testing. Statistical analyses were performed using SPSS for Windows, version 24.0 (SPSS Inc., Chicago, IL, USA), MedCalc, version 9.6.4.0 (MedCalc Software, Ostend, Belgium), and R (Version 3.3.1, Vienna, Austria). Detailed information is given in the Supplementary material online.

Results

Main cohort

Study cohort and characteristics of patients

From April 2006 to August 2015, 3123 patients were available for the analysis of the ESC hs-cTnT 0/1h-algorithm and 2828 patients for the analysis of the ESC hs-cTnI 0/1h-algorithm (Supplementary material online, Figure S2). Older patients differed in multiple characteristics from younger and middle-aged patients, particularly a higher prevalence of pre-existing cardiovascular disorders including AMI and stroke (Table 1, Supplementary material online, Table S2).

Table 1 Baseline characteristics of the patients with complete dataset of high-sensitivity cardiac troponin T in the main cohort

	All patients n = 3123	Young (<55 years) n = 1122	Middle-age (≥55–<70 years) n = 935	Old (≥70 years) n = 1066	P-value
Age (years)	61 (49–74)	45 (37–50)	62 (58–66)	78 (74–82)	
Time from cpo to first study blood draw (h)	5 (2–12)	4 (2–11)	5 (2–12)	5 (3–12)	<0.001
Male gender, n (%)	2116 (68)	860 (77)	645 (69)	611 (57)	<0.001
Risk factors, n (%)					
Hypertension	1911 (61)	382 (34)	622 (67)	907 (85)	<0.001
Hypercholesterolaemia	1538 (49)	314 (28)	526 (56)	698 (66)	<0.001
Diabetes	550 (18)	105 (9)	186 (20)	259 (24)	<0.001
Current smoking	782 (25)	457 (41)	244 (26)	81 (8)	<0.001
History of smoking	1172 (38)	307 (27)	382 (41)	483 (45)	<0.001
History, n (%)					
Coronary artery disease	1038 (33)	172 (15)	327 (35)	539 (51)	<0.001
Previous myocardial infarction	742 (24)	136 (12)	229 (25)	377 (35)	<0.001
Previous revascularization	858 (28)	154 (14)	287 (31)	417 (39)	<0.001
Peripheral artery disease	162 (5)	8 (1)	47 (5)	107 (10)	<0.001
Previous stroke	174 (6)	9 (1)	46 (5)	119 (11)	<0.001
Positive family history	469 (15)	209 (19)	158 (17)	102 (10)	<0.001
ECG findings, n (%)					
Left bundle branch block	117 (4)	11 (1)	25 (3)	81 (8)	<0.001
ST-segment depression	323 (10)	54 (5)	119 (13)	150 (14)	<0.001
T-wave inversion	343 (11)	82 (7)	90 (10)	171 (16)	<0.001
No significant ECG abnormalities	2276 (73)	902 (80)	674 (72)	700 (66)	<0.001
Body mass index (kg/m ²)	27 (24–30)	26 (24–30)	27 (24–30)	26 (24–29)	<0.001
Laboratory findings					
Creatinine clearance (mL/min/m ²)	85 (69–101)	98 (85–112)	85 (73–99)	68 (53–83)	<0.001
Chronic medication, n (%)					
ASA/thienopyridine	1211 (39)	202 (18)	388 (42)	621 (58)	<0.001
β-Blockers	1078 (35)	197 (18)	355 (38)	526 (49)	<0.001
ACEIs/ARBs	1230 (39)	219 (20)	391 (42)	620 (58)	<0.001
Calcium antagonists	467 (15)	61 (5)	141 (15)	265 (25)	<0.001
Nitrates	337 (11)	37 (3)	79 (8)	221 (21)	<0.001
Statins	1110 (36)	182 (16)	383 (41)	545 (51)	<0.001
Diagnostic/therapeutic procedures					
Coronary angiography	715 (23)	137 (12)	260 (28)	318 (30)	<0.001
PCI	402 (13)	76 (7)	143 (15)	183 (17)	<0.001
CABG	60 (2)	7 (1)	22 (2)	31 (3)	<0.001
Ergometry	744 (24)	229 (20)	280 (30)	235 (22)	<0.001
MPS-SPECT	324 (11)	56 (5)	114 (12)	154 (14)	<0.001

Numbers are presented as median (interquartile range) or numbers (%).

ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting; cpo, chest pain onset; ECG, electrocardiography; MPS-SPECT, myocardial perfusion scanning-single photon emission computed tomography; PCI, percutaneous coronary angiography.

Adjudicated final diagnosis

Among patients with complete dataset of hs-cTnT, the adjudicated final diagnosis was NSTEMI in 491/3123 patients (16%), unstable angina in 301/3123 (10%), cardiac symptoms of origin other than coronary artery disease such as tachyarrhythmia, Takotsubo cardiomyopathy, heart failure or myocarditis in 476/3123 (15%), non-cardiac symptoms in 1728/3123 (55%), and unknown in 127/3123 patients (4%). The prevalence of NSTEMI increased with increasing age (young 6.4%, middle-aged 15%, and old 27%,

$P < 0.001$). Distribution of final diagnoses was similar in patients with complete dataset of hs-cTnI ([Supplementary material online](#)).

High-sensitivity cardiac troponin concentrations at presentation according to age and final diagnoses and interaction between age and high-sensitivity cardiac troponin

Concentrations of hs-cTnT and hs-cTnI at presentation showed a moderate-to-high correlation with age in both datasets ($\rho = 0.6$ for




Figure 1 Diagnostic accuracy of high-sensitivity cardiac troponin T and high-sensitivity cardiac troponin I concentrations at presentation to the emergency department for the diagnosis of non-ST-segment elevation myocardial infarction in patients stratified according to age. Receiver operating characteristics curve and corresponding areas under the curves indicating diagnostic accuracy of high-sensitivity cardiac troponin T (blue) and high-sensitivity cardiac troponin I (orange) concentrations at presentation for the diagnosis of acute myocardial infarction in patients stratified according to age into young (<55 years), middle-age (≥55–<70 years), and old (≥70 years) in (A) main cohort, (B) first validation cohort, and (C) second validation cohort. hs-cTnT, high-sensitivity cardiac troponin T; hs-cTnI, high-sensitivity cardiac troponin I.

hs-cTnT and $\rho = 0.49$ for hs-cTnI, respectively, both $P < 0.001$). Old patients had significantly higher hs-cTnT and hs-cTnI concentrations at presentation than young and middle-aged patients, particularly in patients with final diagnoses other than NSTEMI (Supplementary material online, Figure S3A,B). The interaction between age and hs-cTnT concentrations for NSTEMI was significant ($P < 0.001$), but not for hs-cTnI ($P = 0.31$) (Supplementary material online; Supplementary material online, Figure S4A,B).

Diagnostic accuracy of high-sensitivity cardiac troponin T and high-sensitivity cardiac troponin I

Areas under the curves (AUCs) of hs-cTnT concentrations at presentation in young, middle-aged, and old patients were 0.96 (95% CI 0.94–0.98), 0.93 (95% CI 0.91–0.95), and 0.89 (95% CI 0.87–0.91), respectively. Areas under the curves of hs-cTnI concentrations at presentation in young, middle-aged, and old patients were 0.95 (95% CI 0.93–0.97), 0.92 (95% CI 0.90–0.94), and 0.87 (95% CI 0.85–0.90), respectively (Figure 1A).

Diagnostic performance of the ESC high-sensitivity cardiac troponin T 0/1h-algorithm according to age

Among 1122 (36%) young patients, 956/1122 [85% (95% CI 83–87)] were triaged towards rule-out [sensitivity 100% (95% CI 94.9–100), NPV 100% (95% CI 99.6–100)], 92/1122 [8% (95% CI 7–10)] patients were triaged towards rule-in [specificity 97.0% (95% CI 95.8–97.9), PPV 66.3% (95% CI 56.2–75.1)].

Among 935 (30%) middle-aged patients, 606/935 [65% (95% CI 62–68)] were triaged towards rule-out [sensitivity 99.3% (95% CI 96.0–99.9), NPV 99.8% (95% CI 99.1–100)], 141/935 [15% (95% CI 13–17)] patients triaged towards rule-in [specificity 96.1% (95% CI 94.5–97.2), PPV 78.0% (95% CI 70.5–84.1)].

Among 1066 (34%) old patients, 317/1066 [30% (95% CI 27–33)] were triaged towards rule-out [sensitivity 99.3% (95% CI 97.5–99.8), NPV 99.4% (95% CI 97.7–99.8)], 272/1066 [25% (95% CI 23–28)] patients were triaged towards rule-in [specificity 92.7% (95% CI 90.7–94.3), PPV 79.0% (95% CI 73.8–83.5); Table 2, Figure 2A].

One middle-aged and two old patients with NSTEMI were missed (Supplementary material online, Table S3). Detailed diagnostic performance of the ESC hs-cTnT 0/1h-algorithm in decades of age is shown in Figure 2B.

Diagnostic performance of the ESC high-sensitivity cardiac troponin I 0/1h-algorithm according to age

Overall, similar findings emerged when assessing the diagnostic performance of the ESC hs-cTnI 0/1h-algorithm according to age (Figure 3, Table 3, Supplementary material online, Table S3).

Derivation of alternative cut-off criteria for the ESC high-sensitivity cardiac troponin T 0/1h-algorithm

Optimal alternative cut-offs for rule-out were <8 ng/L at presentation in patients presenting with a cpo >3 h or <12 ng/L at presentation and an absolute 1h-change <3 ng/L. The safety was identical to the original ESC hs-cTnT 0/1h-algorithm, but the proportion of patients eligible for direct rule-out increased from 2.2% (95% CI 1.3–3.1) to 11% (95% CI 8.9–13). The proportion of patients ruled-out overall was identical to that of the original ESC 0/1h-algorithm. For rule-in, optimal alternative cut-offs were ≥ 80 ng/L at presentation or an absolute 1h-change ≥ 6 ng/L. These cut-offs improved specificity from 92.7% (95% CI 90.7–94.3) to 96.8% (95% CI 95.3–97.8, $P < 0.01$) and PPV from 79.0% (95% CI 73.8–83.5) to 87.8% (95% CI 82.6–91.6, $P = 0.04$). However, the proportion of patients ruled-in for NSTEMI decreased from 25% (95% CI 23–28) to 21% (95% CI 18–24) and from 18% (95% CI 16–21) to 12% (95% CI 10–14) for direct rule-in; (Supplementary material online, Table S4A). Accordingly, overall efficacy decreased from 55% to 51% ($P < 0.001$).

Derivation of alternative cut-off criteria for the ESC high-sensitivity cardiac troponin I 0/1h-algorithm

Optimal alternative cut-offs for rule-out were <4 ng/L at presentation in patients presenting with cpo >3 h or <6 ng/L at presentation and an absolute 1h-change <3 ng/L. The safety was similar to the original ESC hs-cTnI 0/1h-algorithm (NPV 97.5% vs. 98.1%, $P = 0.67$), and the proportion of patients eligible for rule-out increased from 25% (95% CI 22–27) to 32% (95% CI 29–35) and for direct rule-out from 1.4% (95% CI 0.7–2.4) to 12% (95% CI 10–14) (Supplementary material

online, Table S4B). For rule-in, optimal alternative cut-offs were ≥ 100 ng/L at presentation or an absolute 1h-change ≥ 8 ng/L. These cut-offs significantly improved specificity from 86.4% (95% CI 83.7–88.7) to 90.6% (95% CI 88.3–92.5, $P = 0.01$), while the increase in PPV did not reach statistical significance 67.9% (95% CI 62.4–72.9) to 74.2% (95% CI 68.6–79.2, $P = 0.11$). Again, the proportion of patients ruled-in for NSTEMI decreased from 31% (95% CI 28–34) to 27% (95% CI 24–30) and from 23% (95% CI 20–25) to 16% (95% CI 14–19) for direct rule-in; (Table 3, Supplementary material online, Table S4B). Accordingly, overall efficacy increased from 56% to 58% ($P < 0.03$).

Sex-specific cut-off criteria for the ESC 0/1h-algorithms for use in older patients

The diagnostic performance of derived and validated sex-specific cut-off combinations for use in older patients is shown in the Supplementary material online and Supplementary material online, Table S5A–C.

Subgroup analyses in very early presenters, late presenters, and very old patients

Among 3123 patients with hs-cTnT, 830/3123 patients (27%) presented within 2 h from cpo. For example, in old patients ($n = 226$), 64/226 (28%) were ruled-out (sensitivity 98.5%), 62/226 (27%) ruled-in (specificity 91.1%), and the remaining 100/226 (44%) patients classified as observe (Supplementary material online, Figure S5A). Similar results were obtained for hs-cTnI (Supplementary material online, Figure S5B). The performance of both ESC hs-cTn 0/1h-algorithms in late presenters and very old patients (age ≥ 80 years) is given in the Supplementary material online.

Prognostic performance of the ESC high-sensitivity cardiac troponin T/I 0/1h-algorithms to predict death during follow-up

Survival of young patients triaged towards rule-out, observe and rule-in was 100% at 30-days for all age groups and 99.6%, 96.6%, and 95.1% at 2-years, respectively (all $P < 0.001$). Among middle-aged patients, survival was 99.8%, 98.4%, and 100% at 30-days, and 99.1%, 93.1%, and 96.8% at 2-years, respectively (all $P < 0.001$, $P = 0.06$ for comparison between observe and rule-in). Among old patients, survival was 99.7%, 98.7%, and 94.5% at 30-days, and 93.6%, 82.2% and 75.4% at 2-years, respectively (all $P < 0.001$; Supplementary material online, Figure S6A).

Similar findings emerged when assessing the prognostic performance of the ESC hs-cTnI 0/1h-algorithm (Supplementary material online, Figure S6B) and for the prediction of major adverse cardiac events within 30 days (Supplementary material online).

Validation cohorts

Overall, the characteristics of patients in validation cohort 1 and validation cohort 2 were similar to those of the main cohort (Supplementary material online, Tables S6 and S7).

Diagnostic accuracy of high-sensitivity cardiac troponin T

Areas under the curves of hs-cTnT and hs-cTnI concentrations at presentation in young, middle-aged, and old patients in both validation cohorts were similar to AUCs in the main cohort (Figure 1B,C).

Diagnostic performance of the official ESC high-sensitivity cardiac troponin 0/1h-algorithms and validation of the alternative cut-off criteria in old patients

In both validation cohorts, findings for the ESC hs-cTnT 0/1h-algorithm (and for the hs-cTnI 0/1h-algorithm in the first validation cohort) were similar to the findings of the main cohort. While safety remained high in older patients, specificity among patients triaged towards rule-in and particularly overall efficacy decreased with increasing age (Figure 4, Tables 4–6, Supplementary material online, Figures 7–9).

Prognostic performance of the ESC high-sensitivity cardiac troponin 0/1h-algorithms to predict death during follow-up

Prognostic performance of the ESC 0/1h-algorithms in both validation cohorts was similar to the prognostic performance in the main cohort (Supplementary material online; Supplementary material online, Figure S10).

Discussion

This large multicentre study quantified the impact of age on the performance of the ESC 0/1h-algorithms. In a second step, we derived and externally validated alternative cut-off criteria optimized for the use in older patients. We report eight major findings:

First, increasing age was associated with a higher prevalence of pre-existing cardiovascular disorders. Second, while patients adjudicated to have NSTEMI had comparable hs-cTnT and hs-cTnI concentrations among the three age-strata, hs-cTnT, and hs-cTnI concentrations were significantly higher in older patients with other causes of acute chest discomfort. This finding seems at least in part explained by the higher prevalence of pre-existing cardiovascular disorders and their association with chronic myocardial injury in older patients. Third, accordingly the overlap in hs-cTnT and hs-cTnI concentrations between NSTEMI and other causes of acute chest discomfort was larger resulting in a lower AUC with increasing age. The interaction term (hs-cTn*age) for NSTEMI was statistically significant when using hs-cTnT, but not when using hs-cTnI, possibly suggesting different effects of aging on hs-cTnT vs. hs-cTnI concentrations. Fourth, the prevalence of NSTEMI increased substantially with increasing age and was more than four times higher in older vs. younger patients. Fifth, age had a major impact on the overall diagnostic performance of the ESC 0/1h-algorithm: while safety as quantified




Figure 2 Diagnostic performance of the ESC high-sensitivity cardiac troponin T 0/1h-algorithm according to age in the main cohort. Diagnostic performance of the ESC high-sensitivity cardiac troponin T 0/1h-algorithm in patients stratified according to age into (A) young, middle-age, old, and (B) decades. ^aIf chest pain onset > 3 h; Δ, unsigned change within the first hour; hs-cTnT, high-sensitivity cardiac troponin T; NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value; Prev., prevalence; Sens., sensitivity; Spec., specificity.




Figure 2 Continued.

by sensitivity and NPV was very high in all age-strata, the percentage of patients assigned towards rule-out, the specificity among patients triaged towards rule-in, and particularly overall efficacy decreased with increasing age. As a consequence, the percentage of old patients remaining in the observe zone and usually requiring additional diagnostic testing including a 3h-sample of hs-cTn and cardiac imaging was nearly twice as high as in middle-aged and more than four times as high as in young patients. Due to the increase in AMI prevalence with age, PPV remained high in older patients. Sixth, use of individualized slightly higher cut-offs in older patients maintained very high safety of rule-out, increased specificity of rule-in, reduced overall efficacy for hs-cTnT, while maintaining efficacy for hs-cTnI. Accordingly, the use of slightly higher cut-off concentrations may be considered, particularly if using hs-cTnI. Still, the overall improvement achieved

was modest and needs to be balanced against the increased complexity created by specific cut-offs in elderly patients. Using sex-specific cut-off criteria vs. modified cut-off criteria in older patients did not further increase the overall diagnostic performance of both ESC 0/1h-algorithms. Beyond age, also the time from cpo, sex, and renal function have been shown to affect hs-cTnT and hs-cTnI concentrations. Although preliminary evidence suggests that the effect of these additional confounders overall is smaller as compared to that of age,^{1,2,12,15,34} computerized integration of all confounders might be the most accurate approach once convenient physician-information technology interfaces become available. Seventh, while the vast majority of findings for the ESC 0/1h-algorithm using hs-cTnI mirrored the findings for the ESC 0/1h-algorithm using hs-cTnT, safety of rule-out and accuracy of rule-in were slightly lower for hs-cTnI as

Table 2 Performance of the ESC hs-cTnT 0/1h-algorithm in young, middle-aged and old patients and of alternative cut-off criteria in old patients in the main cohort

Using high-sensitivity cardiac troponin T (n = 3123)							
	Young (<55 years) n = 1122	Middle-age (≥ 55 – <70 years) n = 935	Old (≥ 70 years) n = 1066	P-value ^a	P-value ^b	Alternative cut-offs n = 1066	P-value ^c
Prevalence of NSTEMI	72 (6)	137 (15)	282 (27)	<0.001	<0.001	282 (27)	1
Sensitivity of rule-out	100% (94.9–100)	99.3% (96.0–99.9)	99.3% (97.5–99.8)	0.47	0.98	99.3% (97.5–99.8)	1
NPV of rule-out	100% (99.6–100)	99.8% (99.1–100)	99.4% (97.7–99.8)	0.21	0.24	99.4% (97.8–99.8)	0.27
Specificity of rule-in	97.0% (95.8–97.9)	96.1% (94.5–97.2)	92.7% (90.7–94.3)	0.27	<0.01	96.8% (95.3–97.8)	<0.001
PPV of rule-in	66.3% (56.2–75.1)	78.0% (70.5–84.1)	79.0% (73.8–83.5)	0.05	0.81	87.8% (82.6–91.6)	<0.001
Rule-out, n (%)							
Based on 0h- and 1h-sample	956 (85)	606 (65)	317 (30)	<0.001	<0.001	317 (30)	1
Based on 0h-sample only ^d	305 (27)	128 (14)	23 (2)	<0.001	<0.001	113 (11)	<0.001
Rule-in, n (%)							
Based on 0h- and 1h-sample	92 (8.2)	141 (15)	272 (25)	<0.001	<0.001	224 (21)	<0.001
Based on 0h-sample only	44 (3.9)	86 (9)	195 (18)	<0.001	<0.001	131 (12)	<0.001
Overall efficacy	1048 (93)	747 (80)	589 (55)	<0.001	<0.001	544 (51)	<0.001
Prevalence of NSTEMI in the observational group	11 (15)	26 (14)	65 (14)	0.83	0.95	87 (17)	<0.001

Numbers are presented as numbers (%) and percentage with 95% confidence interval.

NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.

^aP-value for differences between young and middle-aged patients.

^bP-value for differences between middle-aged and old patients.

^cP-value for differences between official and alternative cut-off criteria in old patients.

^dChest pain onset >3 h.




Figure 3 Diagnostic performance of the ESC high-sensitivity cardiac troponin I 0/1h-algorithm according to age in the main cohort. Diagnostic performance of the ESC high-sensitivity cardiac troponin I 0/1h-algorithm in patients stratified according to age into (A) young, middle-age, old, and (B) decades. ^aIf chest pain onset >3 h; Δ , unsigned change within the first hour; hs-cTnI, high-sensitivity cardiac troponin I; NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value; Prev., prevalence; Sens., sensitivity; Spec., specificity.




Figure 3 Continued.

compared to hs-cTnT. At first glance, this finding is surprising as both assays seem to have comparable diagnostic accuracy for NSTEMI,²³ and hs-cTnI-Architect seems to have even higher analytical sensitivity as compared to hs-cTnT-Elecsys.³⁵ This finding is therefore more likely related to the inherent verification bias in favour of hs-cTnT (available among many other information for the adjudication) as compared to hs-cTnI (not available for the adjudication) and the rare, but previously described analytical discrepancies between hs-cTnI and hs-cTnT.^{8,31} Eighth, irrespective of age, patients triaged towards rule-out had very high 30-day survival rates of 99–100%. As expected, 30-day and 1-year or 2-year survival rates were lower in older patients as compared to younger patients.

Our findings extend and corroborate data previously obtained for the diagnostic performance of the ESC 0/1h-algorithm assessed in all-comers with acute chest discomfort.^{7,8,10,22,33} These findings also extend and corroborate more general observations made for the use of hs-cTn in elderly patients.³⁶

The clinical utility of the ESC 0/1h-algorithms also remained high in very old patients (≥80 years) and those presenting very early after cpo. While patients presenting early to the ED were more frequently ruled-in by significant 1h-delta changes, late presenters were primarily ruled-in due to markedly elevated cardiac troponin (cTn) concentrations. This can be explained by the fact that the increase in cTn concentrations is time-dependent. Due to

Table 3 Performance of the ESC hs-cTnI 0/1h-algorithm in young, middle-aged and old patients and of alternative cut-off criteria in old patients in the main cohort

Using high-sensitivity cardiac troponin I (n = 2828)							
	Young (<55 years) n = 1019	Middle-age (≥ 55 – <70 years) n = 836	Old (≥ 70 years) n = 973	P-value ^a	P-value ^b	Alternative cut-offs n = 973	P-value ^c
Prevalence of NSTEMI	64 (6.3)	126 (15%)	259 (27%)	<0.001	<0.001	259 (27%)	1
Sensitivity of rule-out	98.4% (91.7–99.7)	100% (97.0–100)	97.7% (95.0–98.9)	0.16	0.08	97.7% (95.0–98.9)	1
NPV of rule-out	99.9% (99.3–100)	100% (99.2–100)	97.5% (94.7–98.9)	0.45	<0.01	98.1% (95.8–99.1)	0.02
Specificity of rule-in	93.7% (92.0–95.1)	90.8% (88.5–92.8)	86.4% (83.7–88.7)	0.02	0.26	90.6% (88.3–92.5)	<0.001
PPV of rule-in	48.7% (39.8–57.7)	62.9% (55.5–69.7)	67.9% (62.4–72.9)	0.03	0.01	74.2% (68.6–79.2)	<0.001
Proportion ruled-out							
Based on 0h- and 1h-sample	771 (76)	448 (54)	240 (25)	<0.001	<0.001	305 (31)	<0.001
Based on 0h-sample only ^d	178 (18)	66 (7.9)	14 (1.4)	<0.001	<0.001	118 (12)	<0.001
Proportion ruled-in							
Based on 0h- and 1h-sample	117 (12)	175 (21)	302 (31)	<0.001	<0.001	260 (27)	<0.001
Based on 0h-sample only	79 (7.8)	120 (14)	219 (23)	<0.001	<0.001	159 (16)	<0.001
Overall efficacy	890 (87)	623 (75)	543 (56)	<0.001	<0.001	566 (58)	0.03
Prevalence of NSTEMI in the observational group	6 (5)	16 (8)	48 (11)	<0.001	<0.001	60 (15)	0.002

Numbers are presented as n (%) and percentage with 95% confidence interval.

NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.

^aP-value for differences between young and middle-aged patients.

^bP-value for differences between middle-aged and old patients.

^cP-value for differences between official and alternative cut-off criteria in old patients.

^dChest pain onset >3 h.

Table 4 Performance of the ESC hs-cTnT 0/1h-algorithm in young, middle-aged, and old patients and of alternative cut-off criteria in old patients in first validation cohort

Using high-sensitivity cardiac troponin T (n = 1509)							
	Young (<55 years) n = 469	Middle-age (≥ 55 – <70 years) n = 426	Old (≥ 70 years) n = 614	P-value ^a	P-value ^b	Alternative cut-offs n = 614	P-value ^c
Prevalence of NSTEMI	41 (9)	99 (23)	147 (24)	<0.001	0.79	147 (24)	1
Sensitivity of rule-out	100% (91.4–100)	98.0% (92.9–99.4)	100% (97.5–100)	0.36	0.08	99.3% (96.2–99.9)	0.32
NPV of rule-out	100% (98.9–100)	99.1% (96.8–99.8)	100% (97.7–100)	0.08	0.23	99.4% (96.6–99.9)	0.32
Specificity of rule-in	96.3% (94.0–97.7)	92.0% (88.6–94.5)	87.6% (84.3–90.3)	0.01	0.04	93.4% (90.7–95.3)	<0.001
PPV of rule-in	68.0% (54.2–79.2)	75.0% (65.9–82.3)	66.1% (58.7–72.8)	0.36	0.12	77.2% (69.5–83.5)	<0.001
Rule-out, n (%)							
Based on 0h- and 1h-sample	352 (75)	223 (52)	161 (26)	<0.001	<0.001	161 (26)	1
Based on 0h-sample only ^d	28 (6)	6 (1)	4 (1)	<0.001	0.22	12 (2)	0.01
Rule-in, n (%)							
Based on 0h- and 1h-sample	50 (11)	104 (24)	171 (28)	<0.001	0.22	136 (22)	<0.001
Based on 0h-sample only	25 (5)	66 (16)	101 (16)	<0.001	0.68	74 (12)	<0.001
Overall efficacy	402 (86)	327 (76)	332 (54)	0.001	<0.001	298 (48)	<0.001
Prevalence of NSTEMI in the observational group	7 (10)	19 (19)	34 (12)	0.13	0.08	42 (13)	0.008

Numbers are presented as numbers (%) and percentage with 95% confidence interval.

NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.

^aP-value for differences between young and middle-aged patients.

^bP-value for differences between middle-aged and old patients.

^cP-value for differences between official and alternative cut-off criteria in old patients.

^dChest pain onset >3 h.




Figure 4 Diagnostic performance of modified cut-off criteria for use in older patients (≥ 70 years) in all three study cohorts. Diagnostic performance of the (A) ESC high-sensitivity cardiac troponin T 0/1h-algorithm and (B) ESC high-sensitivity cardiac troponin I 0/1h-algorithm using modified cut-off criteria for use in older patients (≥ 70 years). Red numbers indicate modified cut-off values that differ from the official cut-off criteria.

the higher prevalence of NSTEMI, PPV in older patients was even higher (70–80%) as in younger patients, and in a range that most experts consider an acceptable likelihood to initiate invasive management in the majority of these patients. The additional use of short-term changes as criteria within the ESC 0/1h-

algorithms at least in part was able to compensate for the substantially lower specificity of mild elevations in hs-cTn in older patients.³⁶

The lower efficacy observed in older patients is not unique to the ESC 0/1h-algorithms, but seems to be a universal phenomenon of all

Table 5 Performance of the ESC hs-cTnT 0/1h-algorithm in young, middle-aged and old patients and of alternative cut-off criteria in old patients in second validation cohort

Using high-sensitivity cardiac troponin T (n = 1258)							
	Young (<55 years) n = 421	Middle-age (≥ 55 – <70 years) n = 412	Old (≥ 70 years) n = 425	P-value ^a	P-value ^b	Alternative cut-offs n = 425	P-value ^c
Prevalence of NSTEMI	21 (5)	53 (13)	66 (16)	<0.001	0.3	66 (16)	1
Sensitivity of rule-out	100% (84.5–100)	90.6% (79.7–95.9)	98.5% (91.9–99.7)	0.14	0.05	98.5% (91.9–99.7)	1
NPV of rule-out	100% (98.9–100)	98.3% (96.0–99.3)	99.4% (96.6–99.9)	0.01	0.3	99.4% (96.7–99.9)	0.41
Specificity of rule-in	96.0% (93.6–97.5)	94.7% (91.9–96.6)	91.1% (87.7–93.6)	0.12	<0.01	94.2% (91.2–96.1)	<0.001
PPV of rule-in	51.5% (35.2–67.5)	63.5% (49.9–75.2)	59.0% (47.9–69.2)	0.22	0.61	65.6% (53.0–76.3)	0.04
Rule-out, n (%)							
Based on 0h- and 1h-sample	362 (86)	287 (70)	164 (39)	<0.001	<0.001	164 (39)	1
Based on 0h-sample only ^d	63 (15)	43 (10)	25 (6)	0.05	<0.001	52 (12)	<0.001
Rule-in, n (%)							
Based on 0h- and 1h-sample	33 (8)	52 (13)	78 (18)	0.02	0.02	61 (14)	<0.001
Based on 0h-sample only	17 (4)	38 (9)	44 (10)	0.003	0.6	26 (6)	<0.001
Overall efficacy	395 (94)	340 (83)	243 (57)	<0.001	<0.001	227 (53)	0.001
Prevalence of NSTEMI in the observational group	4 (15)	15 (21)	19 (10)	0.53	0.03	25 (13)	0.03

Numbers are presented as numbers (%) and percentage with 95% confidence interval.

NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.

^aP-value for differences between young and middle-aged patients.

^bP-value for differences between middle-aged and old patients.

^cP-value for differences between official and alternative cut-off criteria in old patients.

^dChest pain onset >3 h.

Table 6 Performance of the ESC hs-cTnI 0/1h-algorithm in young, middle-aged and old patients and of alternative cut-off criteria in old patients in first validation cohort

Using high-sensitivity cardiac troponin I (n = 1441)							
	Young (<55 years) n = 459	Middle-age (≥ 55 – <70 years) n = 410	Old (≥ 70 years) n = 572	P-value ^a	P-value ^b	Alternative cut-offs n = 572	P-value ^c
Prevalence of NSTEMI	41 (9)	94 (23)	138 (24)	<0.001	0.66	138 (24)	1
Sensitivity of rule-out	100% (91.4–100)	97.9% (92.6–99.4)	99.3% (96.0–99.9)	0.35	0.35	97.8% (93.8–99.3)	0.16
NPV of rule-out	100% (98.5–100)	98.5% (94.6–99.6)	98.9% (94.2–99.8)	0.05	0.77	97.8% (93.7–99.2)	0.28
Specificity of rule-in	93.5% (90.8–95.5)	88.9% (85–91.9)	85.8% (82.1–88.8)	0.03	0.30	91.5% (88.5–93.8)	<0.001
PPV of rule-in	58.5% (46.3–69.6)	69.6% (60.6–77.2)	65.3% (57.9–72.0)	0.13	0.45	73.4% (65.5–80.0)	<0.001
Proportion ruled-out							
Based on 0h- and 1h-sample	243 (53)	131 (32)	94 (16)	<0.001	<0.001	133 (23)	<0.001
Based on 0h-sample only ^d	16 (4)	7 (2)	7 (1)	0.10	0.53	17 (3)	0.01
Proportion ruled-in							
Based on 0h- and 1h-sample	65 (14)	115 (28)	170 (30)	<0.001	0.57	139 (24)	<0.001
Based on 0h-sample only	36 (8)	74 (18)	94 (16)	<0.001	0.51	73 (13)	<0.001
Overall Efficacy	313 (68)	246 (60)	264 (46)	0.01	<0.001	274 (48)	0.29
Prevalence of NSTEMI in the observational group	3 (2)	12 (7)	26 (8)	0.03	0.67	33 (11)	0.07

Numbers are presented as n (%) and percentage with 95% confidence interval.

NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.

^aP-value for differences between young and middle-aged patients.

^bP-value for differences between middle-aged and old patients.

^cP-value for differences between official and alternative cut-off criteria in old patients.

^dChest pain onset >3 h.

currently available diagnostic algorithms.^{2,3,37} The higher prevalence of cardiovascular comorbidities in older patients invariably reduces the diagnostic performance of clinical assessment, the electrocardiography (ECG), hs-cTn, and cardiac imaging.^{2,3,37}

The exact pathophysiological mechanisms resulting in cardiomyocyte injury in the aging heart are incompletely understood, but seem to include the effect of pre-existing cardiovascular disorders such as previous AMI, hypertensive heart disease, as well as myocardial fibrosis.^{2,3,38}

It is important to highlight that irrespective of the use of the uniform or individualized cut-offs in older patients, the ESC 0/1h-algorithms should always be used in conjunction with full clinical assessment and the ECG. Accordingly, the final sensitivity achieved by the combination of both ESC 0/1h-algorithms with clinical assessment and the ECG will be even slightly higher as that reported for the ESC 0/1h-algorithms only. Vice versa, efficacy will be slightly lower as the clinician will overrule the triage recommendation provided by the algorithm in some patients.

Some limitations merit consideration when interpreting these findings. First, our study was conducted in ED patients with symptoms suggestive of AMI. Further studies are required to quantify the utility of the ESC 0/1h-algorithms in patients with either a higher pre-test probability (e.g. in a coronary care unit setting) or in patients with a lower pre-test probability (e.g. in a general practitioner setting) for AMI. Second, no specific sample size calculation was performed. Although this secondary analysis from an ongoing multicentre study is one of the largest ever performed, it still may have been underpowered for some comparisons. Third, not all patients with acute chest pain had a second set of laboratory measurements at 1 h. The most common reasons for missing blood samples were logistic issues in the ED that precluded blood draw around the 1h-window. However, it is unlikely that the absence of these patients significantly influenced our results. Fourth, although we used the most stringent methodology to adjudicate the presence or absence of AMI including central adjudication by experienced cardiologists and serial measurements of hs-cTn, we still may have misclassified a small number of patients.³⁹ Fifth, our findings are specific to the two hs-cTn assays currently available for routine clinical care. Once other hs-cTn assays will become available for clinical care, additional studies will need to derive and validate a 0/1h-algorithm and examine whether our findings can be generalized to them. Finally, we cannot generalize our findings to patients with terminal kidney failure requiring dialysis, since they were excluded from this study.

Conclusion

While the safety of the ESC 0/1h-algorithms remained very high, increasing age significantly reduced overall efficacy, and the accuracy of rule-in. Alternative slightly higher cut-off concentrations may be considered for older patients, particularly if using hs-cTnI.

Supplementary material

Supplementary material is available at *European Heart Journal* online.

Acknowledgements

We are indebted to the patients who participated in the study and to the emergency department (ED) staff as well as the laboratory technicians of all participating sites for their most valuable efforts. In addition, we wish to thank Irina Klimmeck, RN, Fausta Chiaverio, RN (all University Hospital Basel, Switzerland), Esther Garrido, MD, Joachim Gea, MD (Hospital del Mar, IMIM, Barcelona, Spain), Helena Mañé Cruz, Carolina Isabel Fuenzalida Inostroza (Hospital Clinic, Barcelona, Spain), and Miguel Angel García Briñón (Hospital Clínico San Carlos, Madrid, Spain).

APACE and TRAPID-AMI Investigators who also contributed to this manuscript: Samyut Shrestha, MD, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel; GREAT Network. Dayana Flores, MD, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel; GREAT Network. Michael Freese, SN, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel; GREAT Network. Claudia Stelzig, MS, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel. Caroline Kulangara, PhD, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel. Kathrin Meissner, RN, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel; Nicolas Schaerli, MD, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel; Division of Internal Medicine, University Hospital Basel, University of Basel, both Switzerland; GREAT Network. Deborah Mueller, MD, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel; GREAT Network. Lorraine Szgary, MD, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel; Division of Internal Medicine, University Hospital Basel, University of Basel, both Switzerland; GREAT Network. Stella Marbot, MD, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel; GREAT Network. Beatriz López, MD, GREAT Network; Emergency Department, Hospital Clinic, Barcelona, Catalonia, Spain. Sofia Calderón, MD GREAT Network; Emergency Department, Hospital Clinic, Barcelona, Catalonia, Spain. Esther Rodriguez Adrada, MD, Servicio de Urgencias, Hospital Clínico San Carlos, Madrid, Spain. Damian Kawecki, MD, 2nd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Katowice, Poland. Ewa Nowalany-Koziełska, MD, PhD, 2nd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Katowice, Poland. Eva Ganovská, MD, GREAT Network; Department of Cardiology, University Hospital Brno, Brno, Czech Republic and Medical Faculty, Masaryk University, Brno, Czech Republic. Arnold von Eckardstein, MD, Department of Laboratory Medicine, University Hospital Zurich, Zurich, Switzerland; Isabel Campodarve, MD, Emergency Department, Hospital del Mar, Barcelona, Spain. Michael Christ, MD, Department of Emergency Medicine, Luzerner Kantonsspital, Lucerne, Switzerland. Jorge Ordóñez-Llanos, MD, Department of

Clinical Biochemistry, Institut d'Investigacions Biomèdiques Sant Pau, Barcelona, Spain. Christopher R. de Filippi, MD, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD. James McCord, MD, Henry Ford Heart and Vascular Institute, Henry Ford Health System, Detroit, MI. Richard Body, MD, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. Mauro Panteghini, MD, Department of Biomedical and Clinical Sciences "Luigi Sacco," University of Milan Medical School, Milan, Italy. Thomas Jernberg, MD, Department of Medicine, Karolinska Institutet, Huddinge, Sweden. Mario Plebani, MD, Department of Laboratory Medicine, University Hospital of Padova, Padua, Italy. Franck Verschuren, MD, Department of Acute Medicine, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium. John K. French, MD, Liverpool Hospital and University of New South Wales, Liverpool, NSW, Australia. Robert Christenson, MD, PhD, Department of Pathology, University of Maryland School of Medicine, Baltimore, MD. Silvia Weiser, PhD, Roche Diagnostics Germany, Penzberg, Germany. Garnet Bendig, PhD, Roche Diagnostics Germany, Penzberg, Germany. Peter Dilba, PhD, Roche Diagnostics Germany, Penzberg, Germany.

Funding

Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the Stiftung für kardiovaskuläre Forschung Basel, the University of Basel, Abbott, Beckman Coulter, Biomerieux, Brahms, Roche, Siemens, and Singulex.

Conflict of interest: The authors designed the study, gathered and analysed the data, vouched for the data and analysis, wrote the paper, and decided to publish. Drs J.B., T.N., R.T., P.B., M.R.G., K.W., C.P., T.R., and C.M. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors have read and approved the manuscript. The sponsors had no role in designing or conducting the study and no role in gathering or analysing the data or writing the manuscript. The manuscript and its contents have not been published previously and are not being considered for publications elsewhere in whole or in part in any language, including publicly accessible web sites or e-print servers. We disclose that Dr J.B. received research grants from the University of Basel and the Division of Internal Medicine, the Swiss Academy of Medical Sciences, the Gottfried and Julia Bangerter-Rhyner-Foundation, and speaker honoraria from Siemens. Dr R.T. received research support from the Swiss National Science Foundation (P300PB-167803/1), the University of Basel and the University Hospital of Basel and speaker honoraria/consulting honoraria from Abbott, BRAHMS Thermo Scientific, Roche, Siemens and Singulex. Dr J.T.N. has received a research grant from the German Heart Foundation/German Foundation of Heart Research. Dr B.L. has received research support from Fiom diagnostics and bioMérieux and has served as consultant for Fiom Diagnostics, bioMérieux, Roche Diagnostics, Philips, Thermo-Fischer. Dr M.R.G. received speaker honoraria from Abbott and the research support from the Swiss Heart Foundation. Dr T.R. has received research grants from the Goldschmidt-Jacobson-Foundation, the Swiss National Science Foundation (PASMP3-136995), the Swiss Heart Foundation, the Professor Max Cloëtta Foundation, the Uniscientia Foundation Vaduz, the University of Basel and the Department of Internal Medicine, University Hospital Basel as well as speaker honoraria from Brahms and Roche. Dr C.M. has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the Stiftung für kardiovaskuläre Forschung Basel; Abbott, Alere, Astra Zeneca, Beckman Coulter, Biomerieux,

Brahms, Roche, Siemens, Singulex, Spingotec, and the Department of Internal Medicine, University Hospital Basel, as well as speaker honoraria/consulting honoraria from Abbott, Alere, Astra Zeneca, Biomerieux, Boehringer Ingelheim, BMS, Brahms, Cardiorientis, Novartis, Roche, Siemens, and Singulex. All other authors declare that they have no conflict of interest with this study. The investigated hs-cTn assay were donated by the manufacturers, who had no role in the design of the study, the analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication.

References

1. Twerenbold R, Boeddinghaus J, Nestelberger T, Wildi K, Rubini Gimenez M, Badertscher P, Mueller C. Clinical use of high-sensitivity cardiac troponin in patients with suspected myocardial infarction. *J Am Coll Cardiol* 2017;**70**: 996–1012.
2. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2016; **37**:267–315.
3. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M, Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS. How to use high-sensitivity cardiac troponins in acute cardiac care. *Eur Heart J* 2012;**33**:2252–2257.
4. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. *Clin Chem* 2010;**56**:254–261.
5. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. *N Engl J Med* 2009;**361**:858–867.
6. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Fröhlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Münzel TF, Blankenberg S. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. *N Engl J Med* 2009;**361**:868–877.
7. Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, Moehring B, Ziller R, Hoeller R, Rubini Gimenez M, Haaf P, Potocki M, Wildi K, Balmelli C, Freese M, Stelzig C, Freidank H, Osswald S, Mueller C. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. *Arch Intern Med* 2012;**172**:1211–1218.
8. Rubini Gimenez M, Twerenbold R, Jaeger C, Schindler C, Puelacher C, Wildi K, Reichlin T, Haaf P, Merk S, Honegger U, Wagener M, Druy S, Schumacher C, Krivoshei L, Hillinger P, Herrmann T, Campodarve I, Rentsch K, Bassetti S, Osswald S, Mueller C. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. *Am J Med* 2015;**128**:e4.
9. Boeddinghaus J, Reichlin T, Cullen L, Greenslade JH, Parsonage WA, Hammett C, Pickering JW, Hawkins T, Aldous S, Twerenbold R, Wildi K, Nestelberger T, Grimm K, Rubini-Gimenez M, Puelacher C, Kern V, Rentsch K, Than M, Mueller C. Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarction by use of high-sensitivity cardiac troponin I. *Clin Chem* 2016;**62**: 494–504.
10. Reichlin T, Cullen L, Parsonage WA, Greenslade J, Twerenbold R, Moehring B, Wildi K, Mueller S, Zellweger C, Mosimann T, Rubini Gimenez M, Rentsch K, Osswald S, Müller C. Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. *Am J Med* 2015;**128**:369–379.e4.
11. Reichlin T, Twerenbold R, Wildi K, Gimenez MR, Bergsma N, Haaf P, Druy S, Puelacher C, Moehring B, Freese M, Stelzig C, Krivoshei L, Hillinger P, Jäger C, Herrmann T, Kreutzinger P, Radosavac M, Weidmann ZM, Pershyna K, Honegger U, Wagener M, Vuillomenet T, Campodarve I, Bingisser R, Miró Ò, Rentsch K, Bassetti S, Osswald S, Mueller C. Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. *CMAJ* 2015;**187**:E243–E252.
12. Rubini Gimenez M, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Hillinger P, Wildi K, Jaeger C, Grimm K, Heitzelmann K-F, Sabti Z, Badertscher P, Cupa J, Honegger U, Schaefer N, Kozuharov N, Fay de Lavallaz J, Du Lopez B, Salgado E, Miró Ò, Martín-Sánchez FJ, Adrada ER, Morawiec B, Parenica J, Ganovska E, Neugebauer C, Rentsch K, Lohrmann J, Osswald S, Reichlin T, Mueller C. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction. *JAMA Cardiol* 2016;**1**:912–920.
13. Shah ASV, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruikshank A, Reid A, Stoddart M, Strachan F, Walker S, Collinson PO, Apple FS, Gray AJ,

- Fox KAA, Newby DE, Mills NL. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. *BMJ* 2015;**350**:g7873.
14. Cullen L, Greenslade JH, Carlton EW, Than M, Pickering JW, Ho A, Greaves K, Berndt SL, Body R, Ryan K, Parsonage WA. Sex-specific versus overall cut points for a high sensitivity troponin I assay in predicting 1-year outcomes in emergency patients presenting with chest pain. *Heart* 2016;**102**:120–126.
 15. Mueller-Hennessen M, Lindahl B, Giannitsis E, Biener M, Vafaie M, deFilippi CR, Christ M, Santalo-Bel M, Panteghini M, Plebani M, Verschuren F, Jernberg T, French JK, Christenson RH, Body R, McCord J, Dilba P, Katus HA, Mueller C. Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T—sub-analysis from the TRAPID-AMI study. *Int J Cardiol* 2016;**209**:26–33.
 16. Eggers KM, Jernberg T, Lindahl B. Prognostic importance of sex-specific cardiac troponin t 99th percentiles in suspected acute coronary syndrome. *Am J Med* 2016;**129**:880.e1–880.e12.
 17. Twerenbold R, Wildi K, Jaeger C, Gimenez MR, Reiter M, Reichlin T, Walukiewicz A, Gugala M, Krivoshei L, Marti N, Moreno Weidmann Z, Hillinger P, Puelacher C, Rentsch K, Honegger U, Schumacher C, Zurbriggen F, Freese M, Stelzig C, Campodarve I, Bassetti S, Osswald S, Mueller C. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. *Circulation* 2015;**131**:2041–2050.
 18. Trambas C, Pickering JW, Than M, Bain C, Nie L, Paul E, Dart A, Broughton A, Schneider HG. Impact of high-sensitivity troponin I testing with sex-specific cut-offs on the diagnosis of acute myocardial infarction. *Clin Chem* 2016;**62**:831–838.
 19. Giannitsis E. Sex-specific troponin measures for diagnosis of acute coronary syndrome. *Heart* 2016;**102**:91–92.
 20. Vasudevan A, Singer AJ, Defilippi C, Headden G, Schussler JM, Daniels LB, Reed M, Than MP, Birkhahn R, Smith SW, Barrett TW, Arnold W, Peacock WF, McCullough PA. Renal function and scaled troponin in patients presenting to the emergency department with symptoms of myocardial infarction. *Am J Nephrol* 2017;**45**:304–309.
 21. Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, Lemos De JA. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. *J Am Coll Cardiol* 2014;**63**:1441–1448.
 22. Boeddinghaus J, Nestelberger T, Twerenbold R, Wildi K, Badertscher P, Cupa J, Bürge T, Mächler P, Corbière S, Grimm K, Giménez MR, Puelacher C, Shrestha S, Flores Widmer D, Fuhrmann J, Hillinger P, Sabti Z, Honegger U, Schaeferli N, Kozhuharov N, Rentsch K, Miró Ö, López B, Martin-Sanchez FJ, Rodriguez-Adrada E, Morawiec B, Kawecki D, Ganovská E, Parenica J, Lohrmann J, Kloos W, Buser A, Geigy N, Keller DI, Osswald S, Reichlin T, Mueller C. Direct comparison of 4 very early rule-out strategies for acute myocardial infarction using high-sensitivity cardiac troponin I. *Circulation* 2017;**135**:1597–1611.
 23. Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, Zellweger C, Moehring B, Stallone F, Sou SM, Mueller M, Denhaerynck K, Mosimann T, Reiter M, Meller B, Freese M, Stelzig C, Klimmeck I, Voegelé J, Hartmann B, Rentsch K, Osswald S, Mueller C. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. *Eur Heart J* 2014;**35**:2303–2311.
 24. Twerenbold R, Jaeger C, Gimenez MR, Wildi K, Reichlin T, Nestelberger T, Boeddinghaus J, Grimm K, Puelacher C, Moehring B, Pretre G, Schaeferli N, Campodarve I, Rentsch K, Steuer S, Osswald S, Mueller C. Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction. *Eur Heart J* 2016;**37**:3324–3332.
 25. Nestelberger T, Wildi K, Boeddinghaus J, Twerenbold R, Reichlin T, Giménez MR, Puelacher C, Jaeger C, Grimm K, Sabti Z, Hillinger P, Kozhuharov N, Fay de Lavallaz J, Du Pinck F, Lopez B, Salgado E, Miró Ö, Bingisser R, Lohrmann J, Osswald S, Mueller C. Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 0h/1h-algorithm for the early diagnosis of acute myocardial infarction. *Int J Cardiol* 2016;**207**:238–245.
 26. Boeddinghaus J, Reichlin T, Nestelberger T, Twerenbold R, Meili Y, Wildi K, Hillinger P, Giménez MR, Cupa J, Schumacher L, Schubert M, Badertscher P, Corbière S, Grimm K, Puelacher C, Sabti Z, Widmer DF, Schaeferli N, Kozhuharov N, Shrestha S, Bürge T, Mächler P, Büchi M, Rentsch K, Miró Ö, López B, Martin-Sanchez FJ, Rodriguez-Adrada E, Morawiec B, Kawecki D, Ganovská E, Parenica J, Lohrmann J, Buser A, Keller DI, Osswald S, Mueller C. Early diagnosis of acute myocardial infarction in patients with mild elevations of cardiac troponin. *Clin Res Cardiol* 2017;**106**:457–467.
 27. Neumann JT, Sörensen NA, Schwemer T, Ojeda F, Bourry R, Sciacca V, Schaefer S, Waldeyer C, Sinning C, Renné T, Than M, Parsonage W, Wildi K, Makarova N, Schnabel RB, Landmesser U, Mueller C, Cullen L, Greenslade J, Zeller T, Blankenberg S, Karakas M, Westermann D. Diagnosis of myocardial infarction using a high-sensitivity troponin I 1-hour algorithm. *JAMA Cardiol* 2016;**1**:397.
 28. Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, deFilippi C, McCord J, Body R, Panteghini M, Jernberg T, Plebani M, Verschuren F, French J, Christenson R, Weiser S, Bendig G, Dilba P, Lindahl B, Twerenbold R, Katus HA, Popp S, Santalo-Bel M, Nowak RM, Horner D, Dolci A, Zaninotto M, Manara A, Menassanch-Volker S, Jarausch J, Zaugg C. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin T. *Ann Emerg Med* 2016;**68**:76–87.e4.
 29. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF; STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *Clin Chem* 2015;**61**:1446–1452.
 30. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, Bassetti S, Steuer S, Winkler K, Peter F, Meissner J, Haaf P, Potocki M, Drexler B, Osswald S, Mueller C. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. *Circulation* 2011;**124**:136–145.
 31. Wildi K, Gimenez MR, Twerenbold R, Reichlin T, Jaeger C, Heinzelmann A, Arnold C, Nelles B, Druey S, Haaf P, Hillinger P, Schaeferli N, Kreutzinger P, Tanglay Y, Herrmann T, Moreno Weidmann Z, Krivoshei L, Freese M, Stelzig C, Puelacher C, Rentsch K, Osswald S, Mueller C. Misdiagnosis of myocardial infarction related to limitations of the current regulatory approach to define clinical decision values for cardiac troponin. *Circulation* 2015;**131**:2032–2040.
 32. Rubini Giménez M, Hoeller R, Reichlin T, Zellweger C, Twerenbold R, Reiter M, Moehring B, Wildi K, Mosimann T, Mueller M, Meller B, Hochgruber T, Ziller R, Sou SM, Murray K, Sakarikos K, Ernst S, Gea J, Campodarve I, Vilaplana C, Haaf P, Steuer S, Minners J, Osswald S, Mueller C. Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. *Int J Cardiol* 2013;**168**:3896–3901.
 33. Jaeger C, Wildi K, Twerenbold R, Reichlin T, Rubini Gimenez M, Neuhaus J-D, Grimm K, Boeddinghaus J, Hillinger P, Nestelberger T, Singeisen H, Gugala M, Pretre G, Puelacher C, Wagener M, Honegger U, Schumacher C, Moreno Weidmann Z, Kreutzinger P, Krivoshei L, Freese M, Stelzig C, Dietsche S, Ernst S, Rentsch K, Osswald S, Mueller C. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. *Am Heart J* 2016;**171**:92.e5–102.e5.
 34. Hollander JE, Than M, Mueller C. State-of-the-art evaluation of emergency department patients presenting with potential acute coronary syndromes. *Circulation* 2016;**134**:547–564.
 35. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. *Clin Chem* 2012;**58**:1574–1581.
 36. Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter F, Meissner J, Hochholzer W, Stelzig C, Freese M, Heinisch C, Breidhardt T, Freidank H, Winkler K, Campodarve I, Gea J, Mueller C. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. *Eur Heart J* 2011;**32**:1379–1389.
 37. Mueller C, Giannitsis E, Möckel M, Huber K, Mair J, Plebani M, Thygesen K, Jaffe AS, Lindahl B. Rapid rule out of acute myocardial infarction: novel biomarker-based strategies. *Eur Heart J Acute Cardiovasc Care* 2017;**6**:218–222.
 38. Irfan A, Twerenbold R, Reiter M, Reichlin T, Stelzig C, Freese M, Haaf P, Hochholzer W, Steuer S, Bassetti S, Zellweger C, Freidank H, Peter F, Campodarve I, Meune C, Mueller C. Determinants of high-sensitivity troponin T among patients with a noncardiac cause of chest pain. *Am J Med* 2012;**125**:491–498.e1.
 39. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. *Eur Heart J* 2007;**28**:2525–2538.